Scarica l'app Stockscreener
21.93
5.28%
1.10
Dopo l'orario di chiusura:
22.00
0.07
+0.32%
Precedente Chiudi:
$20.83
Aprire:
$20.84
Volume 24 ore:
306.25K
Relative Volume:
1.23
Capitalizzazione di mercato:
$246.42M
Reddito:
-
Utile/perdita netta:
$-74.14M
Rapporto P/E:
-1.9254
EPS:
-11.39
Flusso di cassa netto:
$-65.70M
1 W Prestazione:
-23.13%
1M Prestazione:
-18.63%
6M Prestazione:
+14.88%
1 anno Prestazione:
+112.91%
Intervallo 1D:
$20.60
$23.59
Intervallo di 1 settimana:
$20.60
$29.80
Portata 52W:
$9.6201
$92.00
Instil Bio Inc Stock (TIL) Company Profile
Nome
Instil Bio Inc
Settore
Industria
Telefono
(972) 499-3350
Indirizzo
3963 MAPLE AVENUE, DALLAS
Confronta TIL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TIL
Instil Bio Inc
|
21.93 | 246.42M | 0 | -74.14M | -65.70M | -11.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Instil Bio Inc Stock (TIL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Perform |
| 2024-04-12 | Downgrade | Jefferies | Buy → Hold |
| 2022-11-01 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-11-01 | Downgrade | Truist | Buy → Hold |
| 2021-08-13 | Iniziato | Robert W. Baird | Outperform |
| 2021-04-13 | Iniziato | Cowen | Outperform |
| 2021-04-13 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-04-13 | Iniziato | Truist | Buy |
Mostra tutto
Instil Bio Inc Borsa (TIL) Ultime notizie
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet - MSN
Instil Bio (TIL) Enhances Axion Bio Board with New Appointment | - GuruFocus
Instil Bio Names John Maraganore, Ph.D., to Board Role - GlobeNewswire
Instil Bio Names John Maraganore, Ph.D., To Board - citybiz
Instil Bio, Inc. Announces the Addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio, Inc., Its Wholly-Owned Subsidiary - MarketScreener
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program - Yahoo Finance
(TIL) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Instil Bio Appoints ‘Seasoned’ Biopharma Exec as Chief Medical Officer - Dallas Innovates
H.C. Wainwright reiterates Instil Bio stock Buy rating amid partnership news By Investing.com - Investing.com South Africa
Instil Bio (TIL) Receives Reiterated Buy Rating from HC Wainwrig - GuruFocus
H.C. Wainwright reiterates Instil Bio stock Buy rating amid partnership news - Investing.com Canada
Instil Bio (TIL) Receives Reiterated Buy Rating from HC Wainwright & Co. | TIL Stock News - GuruFocus
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice - Yahoo Finance
Instil Bio appoints new Chief Medical Officer By Investing.com - Investing.com South Africa
Instil Bio (TIL) Rating Reiterated as Market Perform by JMP Secu - GuruFocus
Instil Bio (TIL) Rating Reiterated as Market Perform by JMP Securities | TIL Stock News - GuruFocus
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire
Instil Bio (TIL) Appoints Jamie Freedman as Chief Medical Officer - GuruFocus
Instil Bio (TIL) Appoints Jamie Freedman as Chief Medical Officer | TIL Stock News - GuruFocus
Instil Bio appoints new Chief Medical Officer - Investing.com
Former Genentech Executive With 15 FDA Approvals Joins Instil Bio to Accelerate Cancer Drug Development - Stock Titan
Instil Bio shares hold as JMP reiterates Market Perform rating By Investing.com - Investing.com India
Instil Bio shares hold as JMP reiterates Market Perform rating - Investing.com Australia
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade - MSN
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference - The Manila Times
Instil Bio CEO Reveals Latest Pipeline Updates at Prestigious Jefferies Healthcare Conference - Stock Titan
Instil Bio Elects Director and Ratifies Auditor - TipRanks
What's Behind The Big Stock Moves? SPRO, TIL, IMAB.... - Nasdaq
Instil Bio Advances Phase 2 Trial in China - TipRanks
(TIL) Proactive Strategies - news.stocktradersdaily.com
Instil Bio: Second Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success (TIL) - Seeking Alpha
H.C. Wainwright lifts Instil Bio stock target to $125 By Investing.com - Investing.com South Africa
H.C. Wainwright lifts Instil Bio stock target to $125 - Investing.com
Instil Bio (TIL) Receives Price Target Upgrade by HC Wainwright & Co. | TIL Stock News - GuruFocus
H.C. Wainwright Boosts Instil Bio (TIL) Price Target Following P - GuruFocus
Instil Bio and ImmuneOnco to Host Investor and Analyst - GlobeNewswire
Instil Bio and ImmuneOnco Announce Joint Investor Breakfast in Chicago to Discuss Immuno-Oncology Developments - Nasdaq
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving ... - Bluefield Daily Telegraph
H.C. Wainwright Boosts Instil Bio (TIL) Price Target Following Positive Data Release | TIL Stock News - GuruFocus
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago - GlobeNewswire
Instil Bio (TIL) Advances Clinical Trials for NSCLC Treatment | - GuruFocus
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in - GlobeNewswire
Instil Bio Inc Azioni (TIL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):